CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery

被引：3

作者：

Robert, Francis ^{[1
]}

Huang, Sidong ^{[1
,3
]}

Pelletier, Jerry ^{[1
,2
,3
]}

机构：

[1] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada

[2] McGill Univ, Oncol, Montreal, PQ H3G 1Y6, Canada

[3] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3G 1Y6, Canada

来源：

CURRENT GENE THERAPY | 2017年 / 17卷 / 04期

关键词：

CRISPR/Cas9; Drug discovery; Target: drug interaction validation; Base editing; Druggable genome; RNA; SCALE CRISPR-CAS9 KNOCKOUT; RESEARCH-AND-DEVELOPMENT; MAMMALIAN-CELLS; SOMATIC HYPERMUTATION; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; TARGET VALIDATION; DRUGGABLE GENOME; CANCER-THERAPIES; PLADIENOLIDE B;

D O I：

10.2174/1566523217666171121164615

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Introduction: The ability of most laboratories to easily access CRISPR/Cas9 engineering tools has caused a revolution in biology. One of the areas that will continue to be impacted by genome editing is the drug discovery process. Objective: CRISPR/Cas9 will not only serve to accelerate the drug discovery pipeline, but also streamline line it by identifying high-value targets, facilitating the validation of drug: target interactions and mechanisms of action, and stimulating the development of phenotype-based high throughput screens as alternatives to target-based assays. Conclusion: We review the literature and hurdles that have been overcome to develop the current generation of tools being used to enrich the drug discovery paradigm.

引用

页码：275 / 285

页数：11

共 86 条

[1] Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia [J].

Alachkar, Houda ;

Santhanam, Ramasamy ;

Harb, Jason G. ;

Lucas, David M. ;

Oaks, Joshua J. ;

Hickey, Christopher J. ;

Pan, Li ;

Kinghorn, A. Douglas ;

Caligiuri, Michael A. ;

Perrotti, Danilo ;

Byrd, John C. ;

Garzon, Ramiro ;

Grever, Michael R. ;

Marcucci, Guido .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

[2]

Aouida Mustapha, 2016, Biochim Open, V3, P72, DOI 10.1016/j.biopen.2016.02.001

[3] Finding effective cancer therapies through loss of function genetic screens [J].

Bernards, Rene .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 2014, 24 :23-29

[4] The landscape of somatic copy-number alteration across human cancers [J].

Beroukhim, Rameen ;

Mermel, Craig H. ;

Porter, Dale ;

Wei, Guo ;

Raychaudhuri, Soumya ;

Donovan, Jerry ;

Barretina, Jordi ;

Boehm, Jesse S. ;

Dobson, Jennifer ;

Urashima, Mitsuyoshi ;

Mc Henry, Kevin T. ;

Pinchback, Reid M. ;

Ligon, Azra H. ;

Cho, Yoon-Jae ;

Haery, Leila ;

Greulich, Heidi ;

Reich, Michael ;

Winckler, Wendy ;

Lawrence, Michael S. ;

Weir, Barbara A. ;

Tanaka, Kumiko E. ;

Chiang, Derek Y. ;

Bass, Adam J. ;

Loo, Alice ;

Hoffman, Carter ;

Prensner, John ;

Liefeld, Ted ;

Gao, Qing ;

Yecies, Derek ;

Signoretti, Sabina ;

Maher, Elizabeth ;

Kaye, Frederic J. ;

Sasaki, Hidefumi ;

Tepper, Joel E. ;

Fletcher, Jonathan A. ;

Tabernero, Josep ;

Baselga, Jose ;

Tsao, Ming-Sound ;

Demichelis, Francesca ;

Rubin, Mark A. ;

Janne, Pasi A. ;

Daly, Mark J. ;

Nucera, Carmelo ;

Levine, Ross L. ;

Ebert, Benjamin L. ;

Gabriel, Stacey ;

Rustgi, Anil K. ;

Antonescu, Cristina R. ;

Ladanyi, Marc ;

Letai, Anthony .

NATURE, 2010, 463 (7283) :899-905

[5] Targeting the translation machinery in cancer [J].

Bhat, Mamatha ;

Robichaud, Nathaniel ;

Hulea, Laura ;

Sonenberg, Nahum ;

Pelletier, Jerry ;

Topisirovic, Ivan .

NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (04) :261-278

[6] The spliceosome as a target of novel antitumour drugs [J].

Bonnal, Sophie ;

Vigevani, Luisa ;

Valcarcel, Juan .

NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (11) :847-859

[7] Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model [J].

Bordeleau, Marie-Eve ;

Robert, Francis ;

Gerard, Baudouin ;

Lindqvist, Lisa ;

Chen, Samuel M. H. ;

Wendel, Hans-Guido ;

Brem, Brigitte ;

Greger, Harald ;

Lowe, Scott W. ;

Porco, John A., Jr. ;

Pelletier, Jerry .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (07) :2651-2660

[8] eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies [J].

Boussemart, Lise ;

Malka-Mahieu, Helene ;

Girault, Isabelle ;

Allard, Delphine ;

Hemmingsson, Oskar ;

Tomasic, Gorana ;

Thomas, Marina ;

Basmadjian, Christine ;

Ribeiro, Nigel ;

Thuaud, Frederic ;

Mateus, Christina ;

Routier, Emilie ;

Kamsu-Kom, Nyam ;

Agoussi, Sandrine ;

Eggermont, Alexander M. ;

Desaubry, Laurent ;

Robert, Caroline ;

Vagner, Stephan .

NATURE, 2014, 513 (7516) :105-+

[9] Innovation - New tools for functional mammalian cancer genetics [J].

Brummelkamp, TR ;

Bernards, R .

NATURE REVIEWS CANCER, 2003, 3 (10) :781-789

[10] Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol [J].

Cencic, Regina ;

Carrier, Marilyn ;

Galicia-Vazquez, Gabriela ;

Bordeleau, Marie-Eve ;

Sukarieh, Rami ;

Bourdeau, Annie ;

Brem, Brigitte ;

Teodoro, Jose G. ;

Greger, Harald ;

Tremblay, Michel L. ;

Porco, John A., Jr. ;

Pelletier, Jerry .

PLOS ONE, 2009, 4 (04)

← 1 2 3 4 5 6 7 8 9 →